February 21 2017
VEXIM: another major step towards the SpineJack® commercialization in the USInvestors
Investors
February 21 2017
VEXIM: another major step towards the SpineJack® commercialization in the USFebruary 2 2017
VEXIM strengthens its intellectual property protection for the SpineJack® in Asia: two patents granted in China and Japan.January 19 2017
VEXIM Strengthens its Management Team, through the appointment of Russell Powers as Vice President and General Manager for its US businessNovember 16 2016
1 VEXIM again awarded « Fastest growing listed company » in the 2016 Technology Fast 50 for Southwestern France by Deloitte In ExtensoSeptember 13 2016
VEXIM signs a distribution agreement with Creatori Health and expands its market to South AfricaSeptember 6 2016
VEXIM announces the registration of its products SpineJack® and Masterflow™ for the treatment of vertebral fractures in AustraliaJune 9 2016
Vexim strengthens its executive teamJanuary 12 2016
VEXIM initiates a new clinical study to support safety, efficacy and cost-effectiveness of SpineJack® compared to conservative treatmentJanuary 7 2016
VEXIM exceeds the threshold of 25,000 SpineJack® implants soldNovember 30 2015
Vexim announces the nomination of Steve Swinson as new Chairman of the Board of DirectorsNovember 4 2015
VEXIM’s excellent performance ranked in Technology Fast 50 for Southwestern France by Deloitte In ExtensoJune 11 2015
VEXIM strengthens his management teamJune 4 2015
VEXIM Initiates International Clinical Study with First Patient Treated to Support Planned 510(k) Application to Market SpineJack® in the United StatesApril 17 2015
Vexim Reports 1-year Results of Comparative Randomized Study of SpineJack® versus Balloon KyphoplastyMarch 10 2015
VEXIM Obtains CE Approval to Market MasterflowTM Injection System in EuropeMarch 2 2015
Excellent long term performances of SpineJack® supported by a 24- month follow-up clinical studyFebruary 19 2015
VEXIM Announces Successful GMP Inspection by Brazil’s National Health Surveillance AgencyFebruary 12 2015
Patents are now granted in Europe, US and China for MasterflowTM, the new high-performance cement delivery systemFebruary 2 2015
VEXIM Announces the First Sales of its MasterflowTM Injection System in the United StatesDecember 10 2014
VEXIM Obtains FDA Approval to Market MasterflowTM Injection System in the United StatesOctober 13 2014
VEXIM to Initiate Clinical Study to Support Planned 510(k) Application to Market SpineJack® in the United StatesSeptember 30 2014
Vexim Reports Six Month Results of Comparative Study of SpineJack® versus Balloon KyphoplastySeptember 8 2014
VEXIM Opens U.S. SubsidiaryJune 9 2014
VEXIM Launches New Generation SpineJack® Device during SFCR Congress in ParisMay 27 2014
VEXIM Announces Successful Completion of Third Expert Symposium on VCF Management in Lisbon, PortugalApril 8 2014
SpineJack®’s CE Mark expanded to all types of vertebral compression fracturesMarch 10 2014
A retrospective study of 178 patients followed over 5 years confirms the excellent long term results of SpineJack® for treating vertebral compression fracturesFebruary 18 2014
VEXIM Strengthens its Management Team, with the Appointment of Sandrine Carle as Marketing DirectorDecember 9 2013
VEXIM launches Interface™, a new biomaterial for fixation promoting bone repairDecember 3 2013
Top-3-ranked THE SPINE JOURNAL publishes a new study proving the excellent performance of the SpineJack®November 19 2013
VEXIM receives the Biotech Future Award (“Prix Biotech d’Avenir”) Technology Fast 50 – Southwest Region, from Deloitte In ExtensoNovember 12 2013
A retrospective study of 77 patients with more than 5 years followup confirms the excellent long term results of SpineJack® for treating vertebral compression fracturesNovember 5 2013
Preliminary results of an international clinical study on 103 patients confirm the excellent performance of SpineJack® in treating vertebral fracturesOctober 9 2013
Vexim strengthens its management structure with the appointment of Jérôme Marzinski as Deputy CEOSeptember 12 2013
Clinical Biomechanics publishes a study proving the excellent performances of the SpineJack®February 28 2013
Acquisition of an innovative system for mixing and injecting orthopaedic cementFebruary 11 2013
Vexim accelerates its European development by establishing a subsidiary in the UKJanuary 8 2013
Vexim accelerates its European development and establishes a subsidiary in SpainSeptember 6 2012
Vexim announces the appointement of Yves-Alain Ratron as Chief Technical OfficerJuly 6 2012
Vexim continues to develop its business across Europe by setting up an Italian subsidiaryJune 6 2012
VEXIM strengthens its management team naming Marie-Pierre Hontas as Clinical Affairs DirectorMarch 6 2012
Vexim continues its development and sets up in Germany to directly market the SpineJack® rangeJanuary 17 2012
VEXIM strengthens its management team appointing: Delphine Gricourt as Director of Marketing and Investor RelationsJanuary 3 2012
Vexim reinforces its management team: Vincent Gardès is appointed as CEOMarch 22 2017
2016: a historic year for VEXIMJanuary 30 2017
Vexim: Amendment of the financial agenda for 2017January 17 2017
VEXIM sets new sales record in the 4th quarter 2016 and solidifies its position as a major player in spine traumaJanuary 3 2017
Bilan annuel du contrat de liquidité VEXIM avec la société de bourse Gilbert Dupont (French Version)January 3 2017
Publication du nombre d’actions composant le capital social et du nombre total de droits de vote (French Version)December 15 2016
VEXIM: Publication of the Shareholders’ Newsletter – December 2016December 12 2016
VEXIM: Financial agenda for 2017October 13 2016
+37% sales increase to €13.3 million as of September 30, 2016 (9 months) New quarterly sales recordSeptember 20 2016
VEXIM: Strong first half 2016 results in line with expectationsSeptember 2 2016
Vexim: Amendment of the financial agenda for 2016September 1 2016
Publication du nombre d’actions composant le capital social et du nombre total de droits de vote (French Version)August 1 2016
Publication du nombre d’actions composant le capital social et du nombre total de droits de vote (French Version)July 12 2016
+40% Revenue Growth in the 1st Half 2016: Upper Range of GoalsJuly 12 2016
Vexim: Amendment of the financial agenda for 2016July 4 2016
Publication du nombre d’actions composant le capital social et du nombre total de droits de vote (French Version)July 4 2016
Bilan semestriel du contrat de liquidité contracté avec la Société de bourse Gilbert Dupont (French Version)June 28 2016
Vexim: Publication of the Shareholders’ Newsletter – June 2016April 14 2016
Strong revenue growth in Q1 2016March 23 2016
2015 financial results Strong Revenue Growth of 34% to €13.9 million and Profitability reached in Q4 2015, strong cash positionMarch 7 2016
Publication du nombre d’actions composant le capital social et du nombre total de droits de vote (French Version)January 14 2016
Strong growth of VEXIM’s sales during 2015: +34%, up to €14 millionDecember 10 2015
VEXIM presents its financial agenda for 2016October 21 2015
Vexim to attend upcoming investor conferences in November and December 2015September 30 2015
Vexim Announces 2015 Half-year ResultsJuly 28 2015
Vexim Announces 2015 First Half Sales ResultsApril 20 2015
VEXIM announces its participation in the Smallcap Event on April 27 and 28 in ParisApril 16 2015
Vexim Announces 2015 First Quarter Sales ResultsMarch 24 2015
Vexim 2014 Annual resultsJanuary 26 2015
VEXIM 2014 sales increase sharply by 69% to €10.3 millionDecember 19 2014
VEXIM Presents its Financial Agenda for 2015October 21 2014
VEXIM SA to Host Key Opinion Leader Meeting and Webcast on October 24 in New York CitySeptember 22 2014
VEXIM Announces Strong 2014 Half-year ResultsJuly 21 2014
Vexim First Half 2014 Sales Rise 93.5 Percent to €4.9 MillionMay 19 2014
Major improvement in patients’ pain, function and quality of life after the Implantation of SpineJack® at 1 yearApril 15 2014
VEXIM doubles its sales in the 1st quarter of 2014, to €2.1mMarch 31 2014
VEXIM shares eligible for new PEA-PME savings planMarch 18 2014
Vexim 2013 annual resultsJanuary 22 2014
Great success of the capital increase Strong oversubscriptionJanuary 16 2014
Vexim 2013 sales: x2.2 to €6.1 millionJanuary 16 2014
VEXIM launches a capital increase without preferential subscription rights by way of public offering aimed at raising approximately EUR 10mOctober 30 2013
VEXIM secures a contingent equity line PACEO® with SOCIETE GENERALEOctober 14 2013
Sharp rise in sales for first nine months of 2013: multiplied by 2.3 to €4.1 millionSeptember 11 2013
First‐half 2013 resultsAugust 12 2013
VEXIM strengthens its equity capital by €2.5 million via an investment by Truffle CapitalJuly 22 2013
Sharp increase in sales over the 1st half of 2013: +133% to €2.5 MillionJune 5 2013
VEXIM postpones its private placementJune 3 2013
Innovative back microsurgery Press release VEXIM launches a private placement of circa €5 millionApril 22 2013
Acceleration in the sales momentum in Q1 2013: +113% to €1.1mMarch 19 2013
Vexim 2012 annual resultsJanuary 10 2013
Vexim: Buoyant growth in activity in 2012September 20 2012
Vexim: results for the 1st half of 2012July 11 2012
Very dynamic activity over the 1st half of 2012May 3 2012
Vexim lists on NYSE AlternextDecember 20 2016
Investors Newsletter – December 2016June 30 2016
Investors Newsletter – June 2016December 4 2015
Investors Newsletter – December 2015